Company Fennec Pharmaceuticals Inc. Nasdaq
Equities
CA31447P1009
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.81 USD | 0.00% |
|
0.00% | 0.00% |
Business Summary
Number of employees: 29
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sodium Thiosulfate
100.0
%
| 2 | 100.0 % | 29 | 100.0 % | +1,335.37% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 2 | 100.0 % | 29 | 100.0 % | +1,335.37% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Rostislav Raykov
CEO | Chief Executive Officer | 48 | 09-07-06 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 09-07-06 |
Mark Gowland
AUD | Comptroller/Controller/Auditor | 52 | 15-10-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chris Rallis
BRD | Director/Board Member | 70 | 11-08-24 |
Khalid Islam
CHM | Chairman | 67 | 14-04-24 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 09-07-06 |
Marco Brughera
BRD | Director/Board Member | 70 | 16-08-09 |
Rostislav Raykov
CEO | Chief Executive Officer | 48 | 09-07-06 |
Jodi Cook
BRD | Director/Board Member | 56 | 19-09-23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 27,323,530 | 22,174,084 ( 81.15 %) | 0 | 81.15 % |
Company contact information
Fennec Pharmaceuticals, Inc.
Research Triangle Park 68 T.W. Alexander Drive
27709, Durham
+919 636 4530
http://www.fennecpharma.com![address Fennec Pharmaceuticals Inc.](https://cdn.zonebourse.com/static/address/121357082.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+20.17% | 126B | |
+24.67% | 118B | |
+24.40% | 27.87B | |
-17.74% | 20.95B | |
-15.73% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |
- Stock Market
- Equities
- FENC Stock
- Stock
- Company Fennec Pharmaceuticals Inc.